In addition to TCA cycle metabolites, other molecules such as soluble LOX-1, Cathepsin S, and LDL-electronegativity have also emerged as promising biomarkers for the prediction of adverse events in ACS (39–41), offering valuable insights into endothelial dysfunction, proteolytic activity, lipoprotein characteristics, and atherosclerosis-related processes. The gene discussed is OLR1; the disease is endothelial dysfunction.